NEW YORK – For many diagnostic firms, developing a portable immunoanalyzer has meant sacrificing sensitivity and specificity. Startup Proxim Diagnostics believes its Profile platform has solved the puzzle and is working to get its cartridge-based, handheld instrument ready for use during the SARS-CoV-2 pandemic.
The fully automated instrument performs enzyme-linked immunosorbent assays, much in the same way as larger immunoanalzyers used in central labs, such as Roche's Cobas or Abbott's Architect systems, said Proxim CEO Mikhail Briman.